RNA
Atrium Therapeutics, Inc.
7.80$
-3.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | -2,547.5% | 107.4% | -546.9% | -1,016.7% | -1,477.3% | -1,245.4% | -2,761.0% | -220.9% | |
| – | – | – | 101.1% | 15.0% | 5.5% | 6.9% | 15.0% | 22.0% | 25.5% | 1.7% | |
| – | – | – | 15.8% | 17.5% | 63.5% | 182.9% | 294.2% | 399.8% | 471.3% | 41.2% | |
| – | – | – | 114.5% | 321.2% | 66.4% | 184.6% | 287.6% | – | – | – | |
| – | – | – | 177.0% | 824.6% | 34.4% | 57.2% | 106.4% | 639.4% | -133.6% | -1.1% | |
| 23.1% | 3.0% | 6.4% | 12.9% | 10.1% | 16.1% | 40.1% | 30.6% | 44.2% | 64.8% | 7.8% | |
| – | – | – | -12.9% | -10.1% | -114.7% | -884.8% | -2,059.4% | -1,360.6% | -7,838.9% | -7.8% | |
| – | – | – | 28.0% | 4.6% | 6.5% | 0.0% | – | – | – | – | |
| – | – | – | 42.7% | 3,134.5% | 6.5% | – | – | – | – | – | |
| – | – | – | 1,314.5% | 718.0% | -69.0% | 0.0% | 0.0% | – | – | – | |
| 5.3% | 331.5% | 672.5% | 1,357.3% | 3,847.9% | 4,008.2% | 1,890.6% | 3,752.9% | 981.8% | 10,942.1% | 228.7% | |
| – | – | – | -1,203.2% | 3,945.1% | 3,346.6% | -10.9% | 216.3% | -1,624.2% | 342.2% | 873.6% | |
| – | – | – | -2,560.4% | 97.2% | -563.0% | -1,056.8% | -1,507.9% | -1,289.7% | -2,825.9% | -228.7% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.